Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 265 Records) |
| Query Trace: Melanoma and NRAS[original query] |
|---|
| The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma. Cancers 2022 9 14 (17): . Boerlin Aurelio, Bellini Elisa, Turko Patrick, Cheng Phil F, Levesque Mitchell P, Dummer Reinhard, Ramelyte Eg |
| Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions. Cancers 2022 9 14 (17): . Zaremba Anne, Jansen Philipp, Murali Rajmohan, Mayakonda Anand, Riedel Anna, Krahl Dieter, Burkhardt Hans, John Stefan, Géraud Cyrill, Philip Manuel, Kretz Julia, Möller Inga, Stadtler Nadine, Sucker Antje, Paschen Annette, Ugurel Selma, Zimmer Lisa, Livingstone Elisabeth, Horn Susanne, Plass Christoph, Schadendorf Dirk, Hadaschik Eva, Lutsik Pavlo, Griewank Kla |
| Prevalence and detection of actionable BRAF V600 and NRAS Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR. Human pathology 2022 Sep . Kao Erica Y, Wakeman Kristina M, Wu Yu, Gross John M, Chen Eleanor Y, Ricciotti Robert W, Liu Yajuan J, Mantilla Jose |
| BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma. JCO precision oncology 2022 Sep 6 e2200018. van Not Olivier J, Blokx Willeke A M, van den Eertwegh Alfons J M, de Meza Melissa M, Haanen John B, Blank Christian U, Aarts Maureen J B, van den Berkmortel Franchette W P J, de Groot Jan Willem B, Hospers Geke A P, Kapiteijn Ellen, Piersma Djura, van Rijn Rozemarijn S, Stevense-den Boer Marion, van der Veldt Astrid A M, Boers-Sonderen Marye J, Jansen Anne M L, Wouters Michel W J M, Suijkerbuijk Karijn P |
| NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma. Frontiers in immunology 2022 13 894110. Li Hongxia, Zhang Qin, Duan Qianqian, Tan Yuan, Sun Tingting, Qi Chua |
| Clinical significance and immune landscape of KIR2DL4 and the senescence-based signature in cutaneous melanoma. Cancer science 2022 7 113 (11): 3947-3959. Mao Rui, Ren Zhengyun, Yang Fan, Yang Peng, Zhang Tongto |
| The Genetics of Early-Stage Melanoma in a Veteran Population. Frontiers in oncology 2022 6 12 887768. Cheung Kevin, Bossler Aaron D, Mott Sarah L, Zeisler Megan, McKillip Julie, Zakharia Yousef, Swick Brian L, Powers Jennifer |
| BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study. Turk patoloji dergisi 2022 6 39 (1): 23-30. Taskin Orhun Cig, Sari Sule Ozturk, Yilmaz Ismail, Hurdogan Ozge, Keskin Metin, Buyukbabani Nesimi, Gulluoglu Mi |
| Actionable Mutation Profile of Sun-Protected Melanomas in South America. The American Journal of dermatopathology 2022 May . Hsieh Ricardo, Nico Marcello M S, Camillo Cláudia M C, Oliveira Kátia K, Carraro Dirce M, Sangueza Martin, Lourenço Silvia |
| Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Frontiers in oncology 2022 5 12 820510. Diefenbach Russell J, Lee Jenny H, Stewart Ashleigh, Menzies Alexander M, Carlino Matteo S, Saw Robyn P M, Stretch Jonathan R, Long Georgina V, Scolyer Richard A, Rizos Hel |
| Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell reports 2022 4 39 (1): 110634. Rajkumar Shivshankari, Berry Diana, Heney Kayla A, Strong Colton, Ramsay LeeAnn, Lajoie Mathieu, Alkallas Rached, Nguyen Tan-Trieu, Thomson Cameron, Ahanfeshar-Adams Mozhdeh, Dankner Matthew, Petrella Teresa, Rose April A N, Siegel Peter M, Watson Ian |
| Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort. The Journal of investigative dermatology 2022 4 142 (10): 2733-2743.e9. Chang Gregory A, Robinson Eric, Wiggins Jennifer M, Zhang Yilong, Tadepalli Jyothirmayee S, Schafer Christine N, Darvishian Farbod, Berman Russell S, Shapiro Richard, Shao Yongzhao, Osman Iman, Polsky Dav |
| Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncology letters 2023 Jan 25 (1): 27. Zablocka Tatjana, Kreismane Madara, Pjanova Dace, Isajevs Serge |
| PRAME Staining in Sinonasal Mucosal Melanoma: A Single-Center Experience. Head and neck pathology 2022 12 . Scheurleer W F Julius, Braunius W Weibel, Tijink Bernard M, Suijkerbuijk Karijn P M, Dierselhuis Miranda P, Meijers Ruud W J, Blokx Willeke A M, de Bree Remco, Breimer Gerben E, Rijken Johannes |
| Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations. Frontiers in cell and developmental biology 2022 12 10 1028854. Crescitelli Rossella, Filges Stefan, Karimi Nasibeh, Urzì Ornella, Alonso-Agudo Tamara, Ståhlberg Anders, Lötvall Jan, Lässer Cecilia, Olofsson Bagge Rog |
| Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples. Cancers 2022 12 14 (23): . Gumà Josep, Peña Karla, Riu Francesc, Guilarte Carmen, Hernandez Anna, Lucía Clara, Martínez-Madueño Francisca, Miranda Maria José, Cabezas Inés, Grifoll Marc, Peralta Sergio, Serrano Sara, Muñoz Félix, Delamo Lola, Roig Barbara, Borràs Joan, Badia Joan, Rodriguez-Balada Marta, Parada Dav |
| Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor. Acta oncologica (Stockholm, Sweden) 2022 10 61 (10): 1263-1267. Mattila Kalle E, Mäkelä Siru, Kytölä Soili, Andersson Emma, Vihinen Pia, Ramadan Susan, Skyttä Tanja, Tiainen Leena, Vuoristo Meri-Sisko, Tyynelä-Korhonen Kristiina, Koivunen Jussi, Kohtamäki Laura, Aittomäki Kristiina, Hernberg Micae |
| Association of NRAS mutations and tertiary lymphoid structure formation with clinical outcomes of adjuvant PD-1 inhibitors for acral melanoma. International immunopharmacology 2023 9 124 (Pt B): 110973. Zeming Mo, Jie Liu, Jinyan Zhang, Yaotiao Deng, Miao Xu, Yu Jia |
| Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma. Clinical & translational immunology 2023 8 12 (8): e1465. John Wen-Cheng Chang, Chien-Jung Huang, Wen-Kuan Huang, Yu-Chao Wang, Jia-Juan Hsieh, Yao-Yu Chang, Yen-Lin Huang, Chia-Ling Wu, Yeh-Han Wang, Shu-Jen Chen, Kien Thiam Tan, Chiao-Ping Chen, Chiao-En |
| Correlation of baseline tumor burden with clinical outcome in melanoma patients treated with ipilimumab. Oncology 2023 8 . Daniela Angelova-Toshkina, Benjamin Weide, Lutz F Tietze, Michelle Hebst, Julia K Tiet |
| A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations. Cancer medicine 2023 7 . Wei Sun, Yu Xu, WangJun Yan, ChunMeng Wang, Tu Hu, ZhiGuo Luo, XiaoWei Zhang, Xin Liu, Yong Ch |
| Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma. Cancers 2023 7 15 (13): . Alyssa Panning, Wolfram Samlowski, Gabriel Allr |
| Prognostic biomarkers for survival in mucosal melanoma. Pigment cell & melanoma research 2023 6 . Julia C Thierauf, Stefan T Kaluziak, Elizabeth Codd, Stacy N Dybel, Soma Jobbagy, Rashi Purohit, Alex A Farahani, Aikaterini Dedeilia, Vivek Naranbhai, Mai P Hoang, Adam S Fisch, Lauren Ritterhouse, Genevieve M Boland, Jochen K Lennerz, A John Iafra |
| Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. European journal of cancer (Oxford, England : 1990) 2023 5 188 140-151. Anne Zaremba, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Claudia Pföhler, Michael Weichenthal, Patrick Terheyden, Andrea Forschner, Ulrike Leiter, Jens Ulrich, Jochen Utikal, Julia Welzel, Martin Kaatz, Christoffer Gebhardt, Rudolf Herbst, Anca Sindrilaru, Edgar Dippel, Michael Sachse, Frank Meiss, Lucie Heinzerling, Sebastian Haferkamp, Carsten Weishaupt, Harald Löffler, Sophia Kreft, Klaus Griewank, Elisabeth Livingstone, Dirk Schadendorf, Selma Ugurel, Lisa Zimm |
| Malignant Melanoma in Older Adults: Different Patient or Different Disease? Cureus 2023 3 15 (2): e34742. Sasson Daniel C, Smetona John T, Parsaei Yassmin, Papageorge Marianna, Ariyan Stephan, Olino Kelly, Clune Jam |
| Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma. Journal of translational medicine 2023 2 21 (1): 78. Huang Rong, Shen Gaigai, Ren Yu, Zheng Kelin, Wang Jiayu, Shi Yan, Yin Jiani C, Qin Lanqun, Zhang Guiying, Zhao Mengke, Su Xinyu, Li Luqiao, Wang Fufeng, Shao Yang, Liu Baorui, Zou Zhengy |
| Characterisation and outcome of RAC1 mutated melanoma. European journal of cancer (Oxford, England : 1990) 2023 2 183 1-10. Lodde Georg C, Jansen Philipp, Herbst Rudolf, Terheyden Patrick, Utikal Jochen, Pföhler Claudia, Ulrich Jens, Kreuter Alexander, Mohr Peter, Gutzmer Ralf, Meier Friedegund, Dippel Edgar, Weichenthal Michael, Sucker Antje, Placke Jan-Malte, Zaremba Anne, Albrecht Lea Jessica, Kowall Bernd, Galetzka Wolfgang, Becker Jürgen C, Tasdogan Alpaslan, Zimmer Lisa, Livingstone Elisabeth, Hadaschik Eva, Schadendorf Dirk, Ugurel Selma, Griewank Kla |
| [Efficacy of adjuvant programmed cell death 1 (PD-1) monoclonal antibody immunotherapy in Chinese patients with resected stage ?-? melanoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2023 11 45 (11): 973-980. Z G Ren, Y Xu, Z Z Hua, Z Y Mo, L W Wang, G B Shi, W L Liu, W Sun, B Q Zheng, C M Wang, Y J Jin, Y Ch |
| Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations. Auris, nasus, larynx 2023 11 . Nayuta Tsushima, Satoshi Kano, Kanako C Hatanaka, Takayoshi Suzuki, Seijiro Hamada, Hiroshi Idogawa, Yuji Nakamaru, Masanobu Suzuki, Yutaka Hatanaka, Akihiro Hom |
| First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. BMC medicine 2023 1 21 (1): 2. Wang Xuan, Luo Zhiguo, Chen Jing, Chen Yu, Ji Dongmei, Fan Li, Chen Ling, Zhao Qian, Hu Pei, Sun Peng, Jia Zhongwei, Guo Jun, Si |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 04, 2023
- Content source: